![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
1. 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine
2. Egyt-341
3. Grandaxin
4. Levotofisopam
5. Tofisopam
6. Tofizopam
1. R-tofisopam
2. Ez15i5d6c1
3. 82059-50-5
4. (5r)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine
5. (+)-(5r)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine
6. Dextofisopam [usan]
7. Dextofisopam (usan/inn)
8. Dextofisopam [usan:inn]
9. Unii-ez15i5d6c1
10. Dextofisopam [inn]
11. Schembl236796
12. Schembl8086913
13. Chembl2107331
14. Dtxsid00231554
15. Zinc608106
16. Db06582
17. D03737
18. Q27277442
19. (5r)-1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine
20. 5h-2,3-benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-, (5r)-
21. 5h-2,3-benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl, (5r)
22. Jpu
Molecular Weight | 382.5 g/mol |
---|---|
Molecular Formula | C22H26N2O4 |
XLogP3 | 3.2 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 6 |
Exact Mass | 382.18925731 g/mol |
Monoisotopic Mass | 382.18925731 g/mol |
Topological Polar Surface Area | 61.6 Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 579 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in irritable bowel syndrome (IBS).
Antidepressive Agents
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)